Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 224

1.

What is the relationship between morning symptoms and measures of disease activity in patients with rheumatoid arthritis?

Boers M, Buttgereit F, Saag K, Alten R, Grahn A, Storey D, Rice P, Kirwan J.

Arthritis Care Res (Hoboken). 2015 Mar 25. doi: 10.1002/acr.22592. [Epub ahead of print]

PMID:
25807939
2.

Clocking in: chronobiology in rheumatoid arthritis.

Buttgereit F, Smolen JS, Coogan AN, Cajochen C.

Nat Rev Rheumatol. 2015 Mar 24. doi: 10.1038/nrrheum.2015.31. [Epub ahead of print] Review.

PMID:
25800214
3.

Circadian rhythms in rheumatology--a glucocorticoid perspective.

Spies CM, Straub RH, Cutolo M, Buttgereit F.

Arthritis Res Ther. 2014 Nov 13;16 Suppl 2:S3. doi: 10.1186/ar4687.

4.

The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis.

Cutolo M, Spies CM, Buttgereit F, Paolino S, Pizzorni C.

Arthritis Res Ther. 2014 Nov 13;16 Suppl 2:S1. doi: 10.1186/ar4685.

5.

Circadian rhythms of cellular immunity in rheumatoid arthritis: a hypothesis-generating study.

Spies CM, Hoff P, Mazuch J, Gaber T, Maier B, Strehl C, Hahne M, Jakstadt M, Huscher D, Burmester GR, Detert J, Kramer A, Buttgereit F.

Clin Exp Rheumatol. 2015 Jan-Feb;33(1):34-43. Epub 2014 Dec 22.

PMID:
25535886
6.

How to mechanistically explain the CONDOR study data.

Spies CM, Stemmler E, Buttgereit F.

Med Hypotheses. 2015 Jan;84(1):14-9. doi: 10.1016/j.mehy.2014.11.007. Epub 2014 Nov 15.

PMID:
25433956
7.

Effects of 60-day bed rest with and without exercise on cellular and humoral immunological parameters.

Hoff P, Belavý DL, Huscher D, Lang A, Hahne M, Kuhlmey AK, Maschmeyer P, Armbrecht G, Fitzner R, Perschel FH, Gaber T, Burmester GR, Straub RH, Felsenberg D, Buttgereit F.

Cell Mol Immunol. 2014 Nov 10. doi: 10.1038/cmi.2014.106. [Epub ahead of print]

PMID:
25382740
8.

Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands (OA TREAT): study protocol for a randomized controlled trial.

Detert J, Klaus P, Listing J, Höhne-Zimmer V, Braun T, Wassenberg S, Rau R, Buttgereit F, Burmester GR.

Trials. 2014 Oct 27;15:412. doi: 10.1186/1745-6215-15-412.

9.

Cellular energy metabolism in T-lymphocytes.

Gaber T, Strehl C, Sawitzki B, Hoff P, Buttgereit F.

Int Rev Immunol. 2015 Jan;34(1):34-49. doi: 10.3109/08830185.2014.956358. Epub 2014 Sep 26.

PMID:
25259409
10.

Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone.

Zheng Y, Basel D, Chow SO, Fong-Yee C, Kim S, Buttgereit F, Dunstan CR, Zhou H, Seibel MJ.

Clin Exp Metastasis. 2014 Dec;31(8):921-33. doi: 10.1007/s10585-014-9680-3. Epub 2014 Sep 16.

PMID:
25223386
11.

Autoimmune rheumatic diseases.

Anaya JM, Shoenfeld Y, Buttgereit F, Gonzalez-Gay MA.

Biomed Res Int. 2014;2014:952159. doi: 10.1155/2014/952159. Epub 2014 Aug 5. No abstract available.

12.

Cytokine expression in human osteoblasts after antiseptic treatment: a comparative study between polyhexanide and chlorhexidine.

Röhner E, Hoff P, Gaber T, Lang A, Vörös P, Buttgereit F, Perka C, Windisch C, Matziolis G.

J Invest Surg. 2015 Feb;28(1):1-7. doi: 10.3109/08941939.2014.941445. Epub 2014 Aug 5.

PMID:
25093465
13.

Impact of morning stiffness on working behaviour and performance in people with rheumatoid arthritis.

Mattila K, Buttgereit F, Tuominen R.

Rheumatol Int. 2014 Dec;34(12):1751-8. doi: 10.1007/s00296-014-3040-0. Epub 2014 May 29.

14.

Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways.

Zheng Y, Chow SO, Boernert K, Basel D, Mikuscheva A, Kim S, Fong-Yee C, Trivedi T, Buttgereit F, Sutherland RL, Dunstan CR, Zhou H, Seibel MJ.

J Bone Miner Res. 2014 Sep;29(9):1938-49. doi: 10.1002/jbmr.2231.

PMID:
24676805
15.

Unraveling the functions of the membrane-bound glucocorticoid receptors: first clues on origin and functional activity.

Strehl C, Buttgereit F.

Ann N Y Acad Sci. 2014 May;1318:1-6. doi: 10.1111/nyas.12364. Epub 2014 Feb 25.

PMID:
24611742
16.

NADPH oxidase 4 represents a potential target for the treatment of osteoporosis.

Hoff P, Buttgereit F.

Cell Mol Immunol. 2014 Jul;11(4):317-9. doi: 10.1038/cmi.2014.9. Epub 2014 Mar 3. No abstract available.

17.

Acute murine antigen-induced arthritis is not affected by disruption of osteoblastic glucocorticoid signalling.

Spies CM, Wiebe E, Tu J, Li A, Gaber T, Huscher D, Seibel MJ, Zhou H, Buttgereit F.

BMC Musculoskelet Disord. 2014 Feb 3;15:31. doi: 10.1186/1471-2474-15-31.

18.

Hypoxia: how does the monocyte-macrophage system respond to changes in oxygen availability?

Strehl C, Fangradt M, Fearon U, Gaber T, Buttgereit F, Veale DJ.

J Leukoc Biol. 2014 Feb;95(2):233-41. doi: 10.1189/jlb.1212627. Epub 2013 Oct 29. Review.

19.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D.

Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. Epub 2013 Oct 25.

20.

EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases.

Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, Caeyers N, Cutolo M, Halliday S, Da Silva JA, Kirwan JR, Ray D, Rovensky J, Severijns G, Westhovens R, Bijlsma JW.

Ann Rheum Dis. 2013 Dec;72(12):1905-13. doi: 10.1136/annrheumdis-2013-203249. Epub 2013 Jul 19.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk